Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E21.95 EPS (ttm)14.78 Insider Own0.10% Shs Outstand235.17M Perf Week4.83%
Market Cap76.28B Forward P/E18.32 EPS next Y17.71 Insider Trans-19.41% Shs Float234.94M Perf Month-19.76%
Income3.49B PEG1.39 EPS next Q3.92 Inst Own92.40% Short Float1.11% Perf Quarter-16.01%
Sales10.30B P/S7.41 EPS this Y58.40% Inst Trans0.12% Short Ratio1.36 Perf Half Y-16.83%
Book/sh53.44 P/B6.07 EPS next Y11.26% ROA23.30% Target Price387.93 Perf Year-1.65%
Cash/sh10.07 P/C32.21 EPS next 5Y15.74% ROE30.70% 52W Range290.85 - 480.18 Perf YTD-4.44%
Dividend- P/FCF23.62 EPS past 5Y29.90% ROI26.20% 52W High-32.45% Beta0.91
Dividend %- Quick Ratio1.90 Sales past 5Y17.30% Gross Margin88.40% 52W Low11.53% ATR13.95
Employees7550 Current Ratio2.20 Sales Q/Q7.00% Oper. Margin44.80% RSI (14)33.21 Volatility3.27% 3.09%
OptionableYes Debt/Eq0.05 EPS Q/Q30.60% Profit Margin33.90% Rel Volume1.58 Prev Close318.78
ShortableYes LT Debt/Eq0.05 EarningsJul 24 BMO Payout0.00% Avg Volume1.91M Price324.38
Recom2.20 SMA20-13.17% SMA50-16.39% SMA200-13.66% Volume3,018,888 Change1.76%
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Aug-03-15 03:45PM  Analyst outlines two possible futures for Biogen: One good, one bad (Video) at bizjournals.com
01:05PM  Biogen Stock Fell for the Week Ending July 24
12:55PM  AbbVie, Inc. Earnings Q2*, 2015
12:27PM  BIIB INVESTORS: The Law Offices of Howard G. Smith Announces An Investigation On Behalf Of Biogen, Inc. Investors Business Wire
09:05AM  Biogen Lowers Its Full-Year 2015 Outlook in 2Q15
08:48AM  Biogen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-02-15 09:12AM  This Latest Study Adds 1 More Piece to the Alzheimer's Puzzle at Motley Fool
Aug-01-15 09:05AM  Tech and Biotech See Big-Time Insider Buying This Week Apple, Biogen, Qualcomm and More at 24/7 Wall St.
08:59AM  The Blockbuster Potential of Biogen Inc's Pipeline at Motley Fool
Jul-31-15 11:06AM  Biogens Experimental Alzheimer Therapy: Limited 2Q15 Success
11:02AM  This is Why Amgen is Soaring at Barrons.com
09:45AM  These are the Biggest Risk to Biotech at Barrons.com
09:06AM  Biogen: Positive 2Q15 Results for Multiple Sclerosis Pipeline Drugs
07:18AM  Key for Investors: Why Did Biotech Stocks Fall?
Jul-30-15 03:00PM  How many multiple sclerosis patients are in the U.S.? No one knows. at bizjournals.com
02:08PM  Biogen Can Get Growth Spurt It Needs With Vertex Deal: Real M&A at Bloomberg
01:04PM  BIOGEN INC. Financials
12:49PM  Biogen: Reports of Its Demise 'Have (Probably!) Been Greatly Exaggerated' at Barrons.com
11:07AM  Biogens Hemophilia Portfolio: Growing Market Share in 2Q15
09:38AM  Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press Releases
09:06AM  Biogens Multiple Sclerosis Drugs Show 2Q15 Growth
07:40AM  Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again at bizjournals.com
Jul-29-15 02:10PM  Here are all the Boston-area biotechs about to buy or get bought at bizjournals.com
11:48AM  Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
11:02AM  Four Reasons Gilead Can Head Higher at Barrons.com
10:06AM  Biogens Weak 2Q15 Tecfidera Performance Dampens Sentiment
08:14AM  5 Stocks Insiders Love Right Now at TheStreet
07:25AM  A vote of confidence for Biogen as chairman buys $3M shares at bizjournals.com
Jul-28-15 05:02PM  Insiders Were Buying Up Shares Of Biogen Inc (BIIB) And These Other Companies Yesterday at Insider Monkey
04:05PM  Market Response to Biogens and Eli Lillys Alzheimers Drugs
02:30PM  Amgen Stock Clears Buy Point Ahead Of Earnings
01:33PM  Gilead Sciences: How Will the Market React to Slowing U.S. Hep-C Sales? at Barrons.com
01:18PM  Is More M&A On The Way For Large-Cap Biotechs?
10:35AM  Biogens 2Q15 Earnings Beat Wall Street Estimates
10:06AM  Eli Lillys Solanezumab: A Possible Cure for Alzheimers?
10:02AM  Wait, Will Allergan Really Buy Biogen or Amgen? at Barrons.com
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc. PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
08:28AM  Watching Twitter for Moves at Teva and Biogen at TheStreet
08:16AM  10 S&P 500 stocks with the biggest declines over the past week at MarketWatch
07:03AM  3 Big Biotech Buybacks That Investors Should Love at Motley Fool
Jul-27-15 08:16PM  Jim Cramer's 'Mad Money' Recap: Beware the Market's FANGs at TheStreet
06:46PM  Which Big-Cap Stocks Are Defying Market Pressure? at Investor's Business Daily
06:00PM  5 Things Biogen's Management Wants You to Know at Motley Fool
04:30PM  Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash at TheStreet
03:02PM  Biogens Alzheimers Drug BIIB037 Registers Some Success in Tests
03:02PM  Biogen Presents Data from PRIME Study of Its Alzheimers Therapy
02:39PM  Heres what people are saying about Biogen and the biotech sector as a whole at bizjournals.com
02:37PM  The Incredible Gilead Faces Its Moment of Truth
02:30PM  4 Stocks Breaking Out on Big Volume at TheStreet
12:52PM  Morgan Stanley Still Likes Biogen After Bleak Earnings
12:29PM  China Weighs on Global Markets at The Wall Street Journal
12:15PM  Biogen Seen as Takeover Target After Fridays Stock Plummet at Bloomberg
12:15PM  Top holdings in health care: Pro
11:45AM  Biogen: Buy the Stock Get the Pipeline for Free at Barrons.com
11:39AM  Teva to Buy Allergan's Generic Drug Unit
11:38AM  Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground at TheStreet
11:33AM  Investors Able to Get Biogen's Pipeline for Free? at The Wall Street Journal
10:58AM  Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
10:42AM  3 Great Values to Buy on the Nasdaq - Analyst Blog
10:42AM  3 Signs That the Healthcare Stock Bubble Might Have Just Popped at Motley Fool
10:30AM  Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up at TheStreet
10:30AM  Biogen (BIIB) Stock Rebounding Following Bernstein Upgrade at TheStreet
10:10AM  Stock Market News for July 27, 2015 - Market News
10:03AM  A Look Ahead: Biotech And Energy ETFs To Watch This Week
10:00AM  Is Biogens Stock Plunge Overreaction? at Insider Monkey
09:52AM  Cramer's Stop Trading: Biogen & GrubHub
07:57AM  Short Sellers Back Off Major Biotechs at 24/7 Wall St.
07:30AM  Biogen Enters Collaboration with the Parkinsons Institute and Clinical Center Business Wire
07:00AM  Biogen's Drop Looks Like Overreaction at Morningstar
06:55AM  Biogen downgraded by Robert W. Baird
04:25AM  Biotech high flyers face gravity test at Financial Times
01:00AM  FCX, CLF, BIIB, COF: Jim Cramer's Views at TheStreet
Jul-26-15 09:57PM  Biotech Stocks Falling Broadly, Here's Why And How Much
08:09PM  10-Q for Biogen Idec, Inc. at Company Spotlight
10:21AM  BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead at 24/7 Wall St.
Jul-25-15 05:00AM  'Fast Money' Panel Weighs Whether to Buy Stocks, Oil on Recent Decline? at TheStreet
Jul-24-15 09:48PM  Biogen Shares Plunge 22% on Poor MS Drug Performance, Slashed Outlook at The Wall Street Journal -22.08%
09:05PM  Buzz Wears Off at Biogen at The Wall Street Journal
08:18PM  Biogen Idec (BIIB) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
06:56PM  Cramer Remix: This stock has lost its mojo at CNBC
06:46PM  Stock Market Today - 07/24/15
06:31PM  Cramer: Not enough leadership for a comeback at CNBC
06:27PM  Biogen Shares Plunge 22%, Outlook Cut at The Wall Street Journal
06:25PM  Who's leading the pack?
05:45PM  Biogen's Terrible, Horrible, No Good, Very Bad Week at Motley Fool
05:39PM  Biogen Dives 22% After Biotech Cuts '15 Sales Guidance
04:46PM  US STOCKS-Wall St slides to end rough week on macro, earnings concerns
04:46PM  Warning Flags: Dow Tumbles, S&P 500 Slides as Biotech Crumbles at Barrons.com
04:26PM  The Buzz Wears Off at Biogen at The Wall Street Journal
04:21PM  Stocks Fall For Fourth Day On Global Growth Worries at Investor's Business Daily
04:06PM  Biogen Inc (BIIB) Faces Biggest Intraday Drop in 7 Years After Missing Earnings Expectations at Insider Monkey
04:02PM  Are you doing this with your trading/investing?
03:31PM  Biogen (BIIB) Stock Plummets on Weak Guidance - Stocks in the News
02:52PM  A Bad Day for Biotechnology ETFs at Barrons.com
02:40PM  Biogen loses $18B in market value, pulls down the rest of biotech with it at bizjournals.com
02:09PM  Biogen: Run Lola Run? at Barrons.com
02:08PM  Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better at TheStreet
01:59PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen, Inc. BIIB Accesswire
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM